Catalent and CTC Bio agree Korean drug delivery partnership

Published: 14-Sep-2012
Drug Delivery Pharmaceutical

Will assist South Korean pharma firms seeking to market products in US and Europe


Catalent Pharma Solutions has entered into a collaboration with CTC Bio of Korea to provide drug delivery solutions to South Korean pharmaceutical companies seeking to market solid oral dose and controlled release products in the US and Europe.

The firms said combining CTC Bio’s leading position in the region with Catalent’s expertise in controlled release formulations, manufacturing network and broad experience in global product launches would provide South Korean companies with unparalleled access to international markets.

Ian Muir, president of Catalent’s Modified Release Technologies business, said the collaboration would enable Catalent to provide South Korean pharmaceutical customers with ‘seamless scale-up and transfer within Catalent’s controlled release capabilities at our Winchester, KY and Somerset, NJ facilities in the US and at Schorndorf, Germany’.

  • Companies:
  • Catalent
See more

You may also like

Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Read more
Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer Denis will be responsible for optimising global operations for the company
  3. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  4. Why use corrugated tubes in heat exchangers? There are a variety of tubular heat exchangers on the market, but for many applications corrugated tubes continue to be preferred over smooth ones. Matt Hale, International Sales & Marketing Director of HRS Heat Exchangers, explains why

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Catalent expands integrated development, manufacturing and supply for modalities

Originally launched in 2019 for early-phase protein therapy development, OneBio Suite offers customers an integrated service
Distribution

Catalent enters commercial supply agreement

Since 2017, Harm Reduction Therapeutics has been working on a low-cost, OTC naloxone product to act as a critical tool to help stem the loss of life
Manufacturing

Catalent expands platform process for viral vectors

Processes can now benefit through increased consistency and efficiency, potentially reducing the time
Manufacturing

Catalent completes $2.2 million expansion to clinical supply facility

The site in Singapore serves the Asia-Pacific region with a wide range of clinical supply services
Drug Delivery

Catalent opens commercial-scale plasmid DNA facility in Belgium

The state-of-the-art facility contains over 12,000 sqft of development and manufacturing space across multiple cleanrooms
Drug Delivery

Catalent to provide supply chain oversight with Case Management Service

It is set to coordinate the scheduling of material collection, the manufacturing slot for the therapy, arrange shipments and continuously manage its status
Research & Development

Developing optimised formulations with minimal drug substance

Advances in in silico and experimental techniques mean that APIs and prototype formulations can be thoroughly characterised using multiple material-sparing assays, allowing the most promising formulation candidates to move on to in vivo studies, reports Lisa Caralli, Science and Technology Director, Pharmaceutics, Catalent
Subscribe now